Eyenovia Inc. announced that it has signed a nonbinding agreement with Formosa Pharmaceuticals whereby the companies will codevelop a formulation of clobetasol propionate ophthalmic suspension 0.05% in combination with the Optejet device for the short-term relief of dry eye disease. Both companies will conduct due diligence and work to execute a definitive agreement that will include the sharing of development costs and the division of profits upon commercialization.